and folate.Due to worsening liver function, DPMAS hemoperfusion was initiated to aid hepatic detoxification.DPMAS treatment was performed in three consecutive sessions.Plasma was separated, passed through the BS330 bilirubin adsorption and HA330-II resin cartridges, and then reinfused.This system removes bilirubin, bile acids, ammonia, and inflammatory mediators.The procedure was done under close monitoring by a multidisciplinary team composed of nephrology, gastroenterology, and obstetrics services.Results: After DPMAS therapy, a significant improvement in liver function was observed.Total bilirubin dropped from 388.1 mol/L to 145.8 mol/L within seven days, while transaminases decreased from ALT 769 to 40 U/L and AST 445 to 43 U/L.Coagulation parameters normalized, and the patient's jaundice, nausea, and malaise resolved.No signs of hepatic encephalopathy or renal dysfunction developed during her hospital stay.She was discharged in stable condition with normalizing liver function tests on follow-up.Six months later, she delivered a healthy full-term baby girl without complications.The favorable outcome highlighted the effectiveness of DPMAS in reversing severe hepatic injury and supporting recovery in pregnancy-related liver failure.
Gautam et al. (Wed,) studied this question.